HOWL

Werewolf Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on developing conditionally activated therapeutics for the treatment of cancer. Headquartered in Watertown, Massachusetts, the company engineers novel immunotherapies using its proprietary PREDATOR platform technology, which creates protein-based therapeutics that remain inactive until activated within the tumor microenvironment. The company's lead product candidate, WTX-124, is a conditionally activated IL-2 prodrug designed to stimulate anti-tumor immunity while minimizing systemic toxicity, currently in Phase 1/2 clinical trials for solid tumors. Werewolf's pipeline also includes WTX-330, targeting indolamine 2,3-dioxygenase 1 (IDO1), and additional early-stage programs leveraging the PREDATOR platform. The company went public in May 2021 through an initial public offering that raised approximately $120 million. As of recent reports, Werewolf maintains strategic collaborations with pharmaceutical partners to advance its technology platform and expand its therapeutic applications. The company's approach addresses a critical challenge in cancer immunotherapy by localizing immune activation to the tumor site, potentially reducing dose-limiting side effects associated with systemic immune stimulation. Werewolf continues to advance its clinical programs while developing next-generation conditionally activated therapeutics across multiple immune pathways.